LM9
LM9 is a potent, orally active MyD88 inhibitor. LM9 blocks TLR4/MyD88 binding, MyD88 homodimer formation, and TLR4/MyD88/NF-κB signaling pathway activation. LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages. LM9 efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. LM9 can be used for fibrosis and atherosclerosis research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2249864-11-5
- Formule: C24H27N5O5S
- Masse moléculaire:497.57
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
|
NF-κB |
TLR4 |
Collagen I |
Collagen IV |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Peritoneal macrophage | IC50 |
0.89 μM
Compound: 15d
|
Antiinflammatory activity in ICR mouse primary peritoneal macrophages assessed as inhibition of LPS-induced TNFalpha production preincubated for 2 hrs followed by LPS stimulation and measured after 22 hrs by ELISA
Antiinflammatory activity in ICR mouse primary peritoneal macrophages assessed as inhibition of LPS-induced TNFalpha production preincubated for 2 hrs followed by LPS stimulation and measured after 22 hrs by ELISA
|
[PMID: 30342423] |
In Vitro
LM9 (5-10 μM; 1 h pretreat) attenuates Palmitic Acid (PA) (HY-N0830)-induced inflammation in mouse peritoneal macrophages by reducing proinflammatory cytokine production and ICAM-1 expression[1].
LM9 (5-10 μM; 1 h pretreat) suppresses PA-induced inflammation and NF-κB signaling activation in H9C2 cells[1].
LM9 (5-10 μM) inhibits PA-induced TLR4/MyD88 binding and MyD88 homodimer formation in HEK293T cells[1].
LM9 (5-10 μM; 1 h pretreat) alleviates PA-induced lipid accumulation and fibrosis in H9C2 cells, decreasing collagen 1/4 and TGF-β expression[1].
LM9 (24 h) does not affect the viability of mouse primary peritoneal macrophages up to 20 μM[2].
LM9 (10-20 μM; 1 h pretreat) reduces inflammatory responses in mouse primary peritoneal macrophages and RAW264.7 cells exposed to ox-LDL (HY-NP013) by suppressing TLR4-MyD88 complex formation, NF-κB activation, and MAPK phosphorylation[2].
LM9 (10-20 μM; 1 h pretreat) suppresses ox-LDL uptake and foam cell formation in mouse primary peritoneal macrophages, which is associated with reduced CD36 expression[2].
LM9 (10-20 μM; 1 h pretreat) reduces ox-LDL-induced ROS production in mouse primary peritoneal macrophages, and this effect is mediated by MyD88 inhibition[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:H9C2 cells
-
Concentration:5; 10 μM
-
Incubation Time:1 h pretreat + 12 h with PA
-
Result:Significantly reduced the mRNA levels of TNF-α, IL-6, ICAM-1, and BNP.
Markly decreased the protein levels of
collagen 1/4 and TGF-β.
-
Cell Line:mouse peritoneal macrophages
-
Concentration:5; 10 μM
-
Incubation Time:1 h + 24 h with PA
-
Result:Reduced PA-induced TNF-α, IL-6, and IL-
1β in mouse peritoneal macrophages.
Exhibited a dose-dependent inhibitory effect on the mRNA levels of proinflammatory gene.
-
Cell Line:H9C2 cells
-
Concentration:5; 10 μM
-
Incubation Time:1 h
-
Result:Markly inhibited the degradation and phosphorylation of IκB-α.
Decreased the accumulation of NF-κB p65 in the nucleus.
Markly decreased the protein levels of
collagen 1/4 and TGF-β.
-
Cell Line:RAW264.7 cells; mouse primary peritoneal macrophages
-
Concentration:10; 20 μM
-
Incubation Time:1 h
-
Result:Inhibited ox-LDL-induced TLR4-MyD88 complex formation.
Inhibited oxLDL-induced activation of MAPKs.
-
Cell Line:RAW264.7 cells
-
Concentration:10; 20 μM
-
Incubation Time:1 h
-
Result:Decreased the accumulation of NF-κB p65 in the nucleus.
In Vivo
LM9 (10 mg/kg; i.g.; every 2 days for 8 weeks) attenuates atherosclerosis in HFD ApoE-/- mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6J mice (18-22 g) fed with HFD for 16 weeks[1]
-
Dosage:5, 10 mg/kg
-
Administration:i.g.; every 2 days; 8 weeks
-
Result:Dose-dependently decreased serum CK-MB, CK, triglyceride, total cholesterol, and LDL levels.
Increased HDL levels.
Improved cardiac function indicators (EF%, FS%).
Reduced myocardial TNF-α accumulation, neutrophil infiltration, and mRNA levels of proinflammatory genes (TNF-α, IL-6, ICAM-1).
Decreased collagen deposition and mRNA/protein levels of profibrotic genes (collagen I, collagen IV, TGF-β, BNP).
Inhibited HFD-induced IκB-α degradation.
-
Animal Model:Male ApoE-/- mice (8-week-old) fed with HFD for 16 weeks[2]
-
Dosage:10 mg/kg
-
Administration:i.g.; every 2 days for 8 weeks
-
Result:Reduced whole aorta plaque area, aortic root lesion area, α-SMA-positive area, collagen deposition.
Reduced serum TNF-α and IL-6 levels, aortic mRNA levels of IL-1β, TNF-α, IL-6, ICAM, and VCAM, CD68-positive macrophage infiltration.
Reduced CD36 expression (mRNA and protein in aortas), and DHE-positive ROS levels in aortas.
Did not alter body weight or serum lipid levels (TG, TCH, LDL, HDL).
Chemical Information
-
CAS No. 2249864-11-5
-
Masse moléculaire 497.57
-
Formule C24H27N5O5S
-
SMILES
O=C(CCN1CCN(CC1)CC2=CC([N+]([O-])=O)=CC=C2)NC3=NC(C4=CC(OC)=C(O)C=C4)=CS3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Fibrosis/Collagen Morphometry
Fibrosis and collagen morphometry is based on the quantitative visualization of fibrillar collagen deposition in tissue sections using histochemical stains such as Sirius Red (Picrosirius Red) or Masson's trichrome, followed by image-based or polarization-enhanced analysis to estimate collagen proportional area as a surrogate of extracellular matrix accumulation during fibrotic remodeling. Sirius Red combined with polarized light microscopy enhances detection of collagen fibers due to birefringence properties, enabling more specific visualization of collagen type I and III fibrils compared to conventional bright-field histology, while whole-section or region-restricted digital morphometry reduces field-selection bias in fibrosis assessment. Alternative quantitative approaches include second harmonic generation (SHG) and two-photon excited fluorescence microscopy, which enable label-free detection of fibrillar collagen and have been validated against histological staining and biochemica
-
Collagen: Sirius Red Staining
Sirius Red or picrosirius red staining is a histochemical method for visualizing collagen-rich extracellular matrix in tissue sections, and collagen fibers are detected as red-stained structures under bright-field microscopy with enhanced birefringence under polarized light. Picrosirius red is useful for assessing total collagen organization, distribution, and fibrosis burden, but polarized color should not be interpreted as a definitive collagen type I versus type III readout because color is affected by fiber orientation, thickness, and packing.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Protocol for Phospho-flow cytometry
Phospho-flow cytometry detects intracellular phosphorylated signaling proteins in single cells using phospho-specific antibodies after rapid fixation and permeabilization; the fluorescence intensity reflects phosphorylation state and therefore kinase-pathway activation, inhibition, or drug response in defined cell subsets. Unlike Western blot, phospho-flow preserves single-cell resolution and can measure signaling heterogeneity in cancer cells, primary immune cells, dissociated mouse tumors, macrophages, organoid-derived cells, and drug-screening samples when validated antibodies and fixation/permeabilization conditions are used.
-
Connective Tissue: Masson's Trichrome/Collagen Trichrome Staining
Masson’s Trichrome (collagen/trichrome staining) is a histological technique that differentially stains tissue compartments using sequential acidic dyes to distinguish collagen from muscle and cytoplasmic components based on dye affinity and tissue permeability differences, enabling visualization of fibrosis and connective tissue architecture in histological sections. The classical formulation typically uses Weigert's iron hematoxylin for nuclear staining, Biebrich scarlet-acid fuchsin for cytoplasm and muscle, and aniline blue (or light green variants) for collagen, producing a characteristic blue/green collagen signal contrasted against red cytoplasm and dark nuclei. The staining principle relies on selective displacement of smaller dye molecules by larger anionic dyes in collagen-rich regions under controlled acidified conditions, which enhances collagen-specific dye retention. This property makes the method widely used for fibrosis assessment in organs such as heart, liver, lung, a
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Pureté et documentation
Références
[1]. Zheng XY, et al. Compound LM9, a novel MyD88 inhibitor, efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. Acta Pharmacol Sin. 2020;41(8):1093-1101. [Content Brief]
[2]. Chen T, et al. A novel MyD88 inhibitor LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages. Toxicol Appl Pharmacol. 2019;370:44-55. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- LM9
- 2249864-11-5
- LM 9
- LM-9
- MyD88
- Toll-like Receptor (TLR)
- NF-κB
- Collagen
- TGF-β Receptor
- p38 MAPK
- Reactive Oxygen Species (ROS)
- MyD88 homodimer formation
- macrophages
- atherosclerosis
- ox-LDL
- TLR4/MyD88/NF-κB signaling pathway
- TLR4/MyD88 binding
- obesity-induced cardiomyopathy
- cardiac cells
- high-fat diet-fed mice
- Inhibitor
- inhibitor
- inhibit